MARKET

ISEE

ISEE

Iveric Bio Inc
NASDAQ
22.65
+0.81
+3.71%
After Hours: 22.55 -0.1 -0.44% 16:28 01/27 EST
OPEN
21.74
PREV CLOSE
21.84
HIGH
22.79
LOW
21.68
VOLUME
2.22M
TURNOVER
0
52 WEEK HIGH
24.33
52 WEEK LOW
8.85
MARKET CAP
3.08B
P/E (TTM)
-16.8916
1D
5D
1M
3M
1Y
5Y
Apellis, Arvinas lower as Wells Fargo downgrades in 2023 biotech preview
Seeking Alpha · 01/03 20:22
BRIEF-Iveric Bio Appoints Pravin Dugel To Its Board Of Directors
Reuters · 01/03 13:05
IVERIC bio out-licenses gene therapy candidates for cash and stock
Seekingalpha · 12/28/2022 11:56
IVERIC bio Subsidiary Sells Assets of Gene Therapy Product Candidates for Treatment of Retinal Diseases
IVERIC bio Subsidiary Sells Assets of Gene Therapy Product Candidates for Treatment of Retinal Diseases
MT Newswires · 12/27/2022 16:59
BRIEF-IVERIC Bio Announces Completion Of Rolling NDA Submission To FDA For Avacincaptad Pegol
Reuters · 12/20/2022 12:34
Iveric Bio Announces Completion Of Rolling NDA Submission To FDA For Avacincaptad Pegol For The Treatment Of Geographic Atrophy
Benzinga · 12/20/2022 12:32
Iveric Bio Submits Final Part of New Drug Application for US FDA Review of Geographic Atrophy Drug Candidate
Iveric Bio Submits Final Part of New Drug Application for US FDA Review of Geographic Atrophy Drug Candidate
MT Newswires · 12/20/2022 09:31
BRIEF-Iveric Bio Borrows The Full $50 Million Tranche Of Term Loan Advances Available At The Company’S Election
Reuters · 12/12/2022 22:29
More
About ISEE
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). It is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.

Webull offers kinds of IVERIC bio Inc stock information, including NASDAQ:ISEE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISEE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISEE stock methods without spending real money on the virtual paper trading platform.